期刊文献+

肿瘤化疗患儿延迟性恶心呕吐的影响因素分析 被引量:2

Analysis of influencing factors and nursing countermeasures of delayed nausea and vomiting in children with tumor chemotherapy
原文传递
导出
摘要 目的探讨肿瘤化疗患儿延迟性恶心呕吐的发生情况及影响因素,为护理人员制订居家照护方案提供依据。方法该研究为前瞻性队列研究,连续选取2022年8月—10月在浙江省某三级甲等儿童专科医院化疗的肿瘤患儿及其照护者作为调查对象,采用巴克斯特干呕脸量表、美国卫生及公共服务部呕吐严重程度评估标准调查患儿延迟性恶心呕吐的发生情况,使用延迟性恶心呕吐影响因素调查表收集相关影响因素,采用二分类Logistic逐步回归进行分析。结果共纳入378例肿瘤化疗患儿,其中229例(60.6%)发生延迟性恶心,144例(38.1%)发生延迟性呕吐,延迟性呕吐主要发生在化疗后1~2 d(50.7%)。Logistic回归分析显示,体表面积、化疗结束后有无负性情绪、有无延迟性恶心呕吐史、是否处于吸烟环境是肿瘤化疗患儿延迟性恶心的影响因素(P<0.05);体表面积、有无延迟性恶心呕吐史、是否合并呼吸或消化系统疾病、化疗药物致吐风险、是否处于吸烟环境、肿瘤类型是肿瘤化疗患儿延迟性呕吐的影响因素(P<0.05)。结论肿瘤化疗患儿延迟性恶心呕吐的发生率较高,尤其在化疗结束后1~2 d。体表面积大、化疗结束后有负性情绪、有延迟性恶心呕吐史是肿瘤化疗患儿发生延迟性恶心的危险因素;体表面积大、有延迟性恶心呕吐史、合并呼吸或消化系统疾病、化疗药物致吐风险高、罹患实体肿瘤是肿瘤化疗患儿发生延迟性呕吐的危险因素。建议护理人员根据相关危险因素制订预防措施,开展居家照护指导,以降低肿瘤化疗患儿延迟性恶心呕吐的发生率。 Objective To explore the occurrence and influencing factors of delayed nausea and vomiting in children with tumor chemotherapy,so as to provide bases for doctors and nurses to formulate home care plans.Methods A prospective cohort study was conducted,and a toll of consecutive children who received chemotherapy and their caregivers in a tertiary A Children’s Hospital in Zhejiang Province from August to October 2022 were enrolled as the subjects of investigation.Baxter Retching Faces Scale and United States Department of Health and Human Services Common Adverse Event evaluation criteria were used to evaluate the incidence of delayed nausea and vomiting.The influencing factors of delayed nausea and vomiting were collected by questionnaire and analyzed by binary logistic stepwise regression.Results A total of 378 children with tumor chemotherapy were included,of which 229(60.6%)developed delayed nausea and 144(38.1%)developed delayed vomiting.Delayed vomiting mainly occurred 1-2 days after chemotherapy(50.7%).Logistic regression analysis showed that body surface area,negative emotion,history of delayed nausea and vomiting,and smoking environment were the influencing factors of delayed nausea in children with tumor chemotherapy.Body surface area,history of delayed nausea and vomiting,complicated with respiratory or digestive system diseases,vomiting risk of chemotherapeutic drugs,smoking environment and tumor type were the influencing factors of delayed vomiting in children with tumor chemotherapy(P<0.05).Conclusion The incidence of nausea and vomiting associated with delayed chemotherapy was high in children with tumor,especially at 1~2 days after chemotherapy.Large body surface area,negative emotion and history of delayed nausea and vomiting are the high-risk factors of delayed nausea in children with tumor chemotherapy;large body surface area,history of delayed nausea and vomiting,complicated with respiratory or digestive system diseases,high vomiting risk of chemotherapeutic drugs and solid tumors are high risk factors for delayed vomiting in children undergoing tumor chemotherapy.It is suggested that medical staff should formulate preventive measures according to relevant risk factors and carry out home care guidance to reduce the incidence of delayed nausea and vomiting in children undergoing tumor chemotherapy.
作者 虞露艳 林楠 周莹 白冠男 何昕彧 褚小艺 张怡然 吴倩 赵丹 郭梦颖 诸纪华 YU Luyan;LIN Nan;ZHOU Ying;BAI Guannan;HE Xinyu;CHU Xiaoyi;ZHANG Yiran;WU Qian;ZHAO Dan;GUO Mengying;ZHU Jihua
出处 《中华护理杂志》 CSCD 北大核心 2023年第20期2494-2502,共9页 Chinese Journal of Nursing
关键词 肿瘤 化疗 恶心呕吐 影响因素分析 儿科护理学 Neoplasms Chemotherapy Nausea and Vomiting Root Cause Analysis Pediatric Nursing
  • 相关文献

参考文献5

二级参考文献61

  • 1Wickham R. Evolving treatment paradigms for chemotherapy-in- duced nausea and vomiting[J]. Cancer Control, 2012, 19 (2 Suppl ) : 3- 9.
  • 2Jordan K, Hinke A, Grothey A, et al. A meta-analysis comparing the efficacy of four 5-HT3-receptor antagonists for acute chemo- therapy-induced emesis [ J ]. Support Care Cancer, 2007, 15 (9) : 1023-1033.
  • 3Feyer P, Jordan K. Update and new trends in antiemetic therapy : the continuing need for novd therapies [J ].Ann Oncol, 2011, 22 (1) :30-38.
  • 4Likun Z, Xiang J, Yi B, et al. A systematic review and meta-a- nalysis of intravenous palonosetron in the prevention of chemother- apy-induced nausea and vomiting in adults [ J ]. Oneologist, 2011, 16(2) :207-216.
  • 5Navari RN. Treatment of chemotherapy-induced nausea[ J]. Com- mun Oncol, 2012, 9(1) :20-26.
  • 6Roila F, Herrstedt J, Aapro M, et al. Guideline update for MAS- CC and ESMO in the prevention of chemotherapy-and radiotherapy-induced nausea and vomiting: Results of the Perugia consensus conference[ J]. Ann Oncol, 2010,21 ( Suppl 5) : 232 - 243.
  • 7Basch E, Prestrud AA, Hesketh PJ, et al. Antiemetics: American Society of Clinical Oncology clinical practice guideline update[J]. J Clin Oncol, 2011, 29(32) :4189-4198.
  • 8Saito M, Aogi K, Sekine I, et al. Palonosetron plus dexametha- sone versus granisetron plus dexamethasone for prevention of nausea and vomiting during chemotherapy: a double-blind, double-dummy, randomised, comparative phase III trial [ J ]. Lan-ect Oncol, 2009, 10(2) : 115-124.
  • 9Brugnatelli S, Gattoni E, Grasso D, et al. Single-dose palonosetron and dexamethasone in preventing nausea and vomiting induced by moderately emetogenic chemotherapy in breast and colorectal cancer patients[ J ]. Tumori, 2011,97 (3) : 362-366.
  • 10Aogi K, Sakai H, Yoshizawa H, et al. A phase III open-labeL study to assess safety and efficacy of palonosetron for preventing chemotherapy-induced nausea and vomiting ( C1NV ) in repeated cycles of emetogenic chemotherapy [ J ]. Support Care Cancer, 2012, 20(7) :1507-1514.

共引文献90

同被引文献12

引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部